Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

F ollowing the release of widely touted study results for a Gilead Sciences HIV treatment, a new analysis finds the medicine — called lenacapavir — could be made for as little as $26 to $40 ...

W hen drugmaker Gilead Sciences announced interim late-stage trial results of its injectable HIV prevention drug last month, researchers, advocates and Wall Street collectively rejoiced.

Gilead’s COMPASS Initiative ®, a commitment of over $100 million over 10 years, is one of the largest examples of partnerships in the US that supports organizations working to address the HIV ...

Gilead's longtime goal has been to develop a cure for HIV. And now the biotech doesn't just have one pipeline candidate in clinical testing that could achieve that goal -- it has four.